Trial reportBritish journal of cancer2023
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Trial report in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Colorectal Cancer: A Landscape of New Potential Radiopharmaceuticals.Molecular diagnosis & therapy · 2026Review
- Immuno-cytotoxic convergence: integrating antibody‒drug conjugates and immunofusion proteins to overcome resistance in gastrointestinal cancers.Journal of hematology & oncology · 2026Review
- Nectin-4 expression in vulvar squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2026Article
- TROP2-Targeted Therapeutics in Development to Treat Gastrointestinal Tumors.Molecular diagnosis & therapy · 2026Review
- Staging metastatic urothelial cancer with Nectin-4 imaging using Gallium-68-N188 PET/CT.BJU international · 2026Article
- Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4.Human vaccines & immunotherapeutics · 2025Review
- [Trop-2 expression in solid tumors : Expanded protein diagnostics within the molecular tumor board].Pathologie (Heidelberg, Germany) · 2025Article
- METTL3-mediated mActa biochimica et biophysica Sinica · 2025Article
- Comparative immunohistochemical expression of TROP2 in brain metastatic and primary tumors.American journal of cancer research · 2025Article
- Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors.The oncologist · 2024Article
- Novel Anti-Trop2 Nanobodies Disrupt Receptor Dimerization and Inhibit Tumor Cell Growth.Pharmaceutics · 2024Article
- TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis.The journal of pathology. Clinical research · 2024Article
- Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs.Pharmaceuticals (Basel, Switzerland) · 2024Review
- DNA demethylation and tri-methylation of H3K4 at the TACSTD2 promoter are complementary players for TROP2 regulation in colorectal cancer cells.Scientific reports · 2024Article
- The Relationship between Trop-2, Chemotherapeutic Drugs, and Chemoresistance.International journal of molecular sciences · 2023Review
- Prognostic Potential of Nectin Expressions in Colorectal Cancer: An Exploratory Study.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrop-2 and Nectin-4 are transmembrane proteins overexpressed in many tumours and targets of antibody-drug conjugates (ADC). In metastatic colorectal cancer (mCRC), the role of Trop-2 and Nectin-4 has been poorly investigated.
methodsTumour samples of patients randomised in the phase III TRIBE2 were assessed for Trop-2 and Nectin-4 expression.
resultsThree hundred eighty-six tumours were assessed for Trop-2 expression. 90 (23%), 115 (30%) and 181 (47%) were Trop-2 high, medium and low, respectively. Patients with low Trop-2 tumours achieved longer PFS (12 versus 9.9 months, p = 0.047) and OS (27.3 versus 21.3 months, p = 0.015) than those with high/medium Trop-2 tumours. These findings were confirmed in multivariate analysis (p = 0.022 and p = 0.023, respectively). A greater OS benefit from treatment intensification with FOLFOXIRI/bevacizumab was observed in patients with high/medium Trop-2 tumours (p-for-interaction = 0.041). Two hundred fifty-one tumours were assessed for Nectin-4 expression. Fourteen (5%), 67 (27%) and 170 (68%) were high, medium and low, respectively. No prognostic impact was observed based on Nectin-4 expression and no interaction effect was reported between Nectin-4 expression groups and treatment arm.
conclusionsIn mCRC, expression levels of Trop-2 and Nectin-4 are heterogeneous, suggesting a target-driven development of anti-Trop2 and anti-Nectin-4 ADCs. Medium/high Trop-2 expression is associated with worse prognosis and higher benefit from chemotherapy intensification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.